Showing papers in "The Breast in 2018"

TL;DR: A strong and united global effort among healthcare professionals, including clinicians, oncologists, pharmaceutical manufacturers, payers, and policy makers, and with advocates, families, and patients, is necessary to improve the outcome and quality of life for patients with mBC.

TL;DR: Compared with immediate techniques, delayed reconstruction following mastectomy was associated with lower rates of overall and major complication, while providing equivalent patient satisfaction and quality of life benefits, although immediate reconstruction is still the preferred choice of most patients and surgeons.

TL;DR: The present review addresses the mechanisms of breast cancer immunoediting, its cell complexity and prognostic/predictive relevance, providing evidence that TILs represent one the most promising biomarkers for BC patients.

TL;DR: PPBCT remains to be a prevalent and complex clinical issue, despite a variety of different techniques and treatments, and a greater understanding of BC treatments and their impact on PPBCT may help identify potential risk factors, prevention and pain management strategies.

TL;DR: New strategies in development to treat HER2-positive metastatic breast cancer referring to the mechanisms of action of new drugs and new combinations including results reported so far are examined.

TL;DR: The main molecular alterations of FGFRs, as well as the available preclinical and clinical data with FGFR inhibitors in breast cancer, are summarized, and new opportunities for the clinical development of these agents in patients with breast cancer are discussed.

TL;DR: Further educational initiatives are needed to improve physicians' knowledge and adherence to available guidelines when addressing fertility and pregnancy-related issues in young breast cancer patients.

TL;DR: MRI had a higher sensitivity and PET/CTHad a higher specificity in predicting the pathologic response after NAC in patients with breast cancer, according to the area under the SROC curve and anatomic discriminative resolution.

TL;DR: The results suggest that CBD treatment induces an interplay among PPARγ, mTOR and cyclin D1 in favor of apoptosis induction in both ER-positive and triple negative breast cancer cells, proposing CBD as a useful treatment for different breast cancer subtypes.

TL;DR: In several high-income countries, the fall in breast cancer mortality, due to improved treatment and diagnosis, has been the major success in the management of any common cancer over the last three decades, and there are persistent disparities in the global decline in Breast cancer, which call for urgent management improvements in several areas of the world.

TL;DR: The prognostic stage provided accurate prognostic information for LABC compared with anatomic TNM stage, which will lead to accuracy in prognosis prediction and optimal treatment selection, and therefore, better outcomes.

TL;DR: The importance of long term monitoring and subsequently coaching of physical activity after breast cancer surgery seems important to monitor physical activity levels in breast cancer patients and advice these patients to stay active after surgery and return to pre-operativeActivity levels in the long term as well.

TL;DR: It was found that health portals were of higher quality whilst commercial and professional websites were of poorer quality in terms of JAMA criteria, and readability was higher than previously reported for other conditions, and Google ranked websites with better readability higher.

TL;DR: Both isolated IBTR and CBC incidence rates steadily increased with the length of follow-up, indicating that IB TR and CBC occur even more than 15 years after diagnosis.

TL;DR: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients and education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.

TL;DR: Although pTRAM flaps are being replaced by fTRAM and DIEP flaps, which exhibit fewer complications related to flap ischemia and donor site morbidity, it was unclear from the literature which flap type was most beneficial regarding flap vascularity and donor sites morbidity.

TL;DR: Following bilateral prophylactic NSM and immediate subcutaneous reconstruction with TiLoop®, patients demonstrated high levels of satisfaction and quality of life as measured by BREAST-Q.

TL;DR: Evidence is provided that disease progression in patients with metastatic breast cancer in a real-world registry has a significant negative impact on HRQoL as measured by minimally important deterioration (MID) in global HRqoL score.

TL;DR: Preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC is reported.

TL;DR: Recent evidence suggests that lymphocytes infiltrating breast cancers and found in the tumor stroma are strong prognostic indicators of a beneficial disease outcome.

TL;DR: Radiomics features in patients with dense breasts and negative mammography appear to differ between cancerous and normal breast tissue, with evidence of correlation with tumor size and estrogen receptors.

TL;DR: Cancer distress screening and subsequent referral for psychosocial intervention has been mandated for continued cancer center accreditation and increasing emphasis is being placed on the referral component, ensuring that patient distress is not only identified but also effectively treated.

TL;DR: Interval breast cancer rate amongst screening participants in the STORM trial was marginally lower (and screening sensitivity higher) than estimates amongst 2D-screened women; these findings should be interpreted with caution given the small number of interval cases and the sample size of the trial.

TL;DR: For the appropriate patients with moderate to large sized breasts with breast cancer, large volume displacement oncoplastic surgery is cost-effective compared to mastectomy with single staged implant reconstruction.

TL;DR: US imaging is insufficient to predict pathologic complete response (pCR) with adequate accuracy after NACT, and pathological response was most accurately predicted for TN cancers.

TL;DR: T-DM1 is active in breast cancer patients with BMs and at a median follow-up of 16 months, median cumulative progression-free survival (PFS) was 7 months, and overall survival was 14 months.

TL;DR: It is suggested that persistent pain after breast reconstruction may not necessarily reflect surgery-induced pain, and future research will need to determine those factors that contribute to long-term pain following breast reconstruction.

TL;DR: Prophylactic ACE inhibitor does not attenuate development of LV dysfunction or heart failure in patients receiving anthracycline chemotherapy and beta-blocker attenuated reduction in LVEF and new heart failure diagnosis.

TL;DR: A review looks back at the theory of the cancer immunity cycle and mechanism of action behind immune checkpoint inhibitors and goes on to explore their role within the various subtypes of breast cancer.

TL;DR: A descriptive review of the evidence on the impact of BD legislation can inform research priorities where BD legislation has been introduced and can be used to guide world-wide policy or practice decisions where BD Legislation may be under debate or contemplation.